December 18, 2007 / 12:33 PM / 10 years ago

S.Korea's Celltrion gets FDA OK to make Bristol-Myers' Orencia

1 IN. DI LETTURA

Dec 18 (Reuters) - South Korean biotech firm Celltrion Inc said it received approval from U.S. health regulators to serve as a contract manufacturer to make Bristol-Myers Squibb Co's (BMY.N) rheumatoid arthritis drug Orencia.

The supplemental biological licence application was submitted by Bristol-Myers to meet expected long-term demand for the drug, Celltrion said in a statement. (Reporting by Nachiket Kelkar in Bangalore; Editing by Pratish Narayanan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below